You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH)控股子公司獲藥品臨牀試驗批准
格隆匯 01-13 16:35

格隆匯1月13日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物技術股份有限公司(以下簡稱“復宏漢霖”)及其控股子公司上海復宏漢霖生物製藥有限公司(以下簡稱“漢霖製藥”)收到國家藥監局關於同意其研製的重組抗CD38全人單克隆抗體注射液(即HLX15;以下簡稱“該新藥”)用於多發性骨髓瘤治療臨牀試驗的批准。

復宏漢霖及漢霖製藥擬於近期條件具備後於中國境內(不包括港澳台地區,下同)開展該新藥的Ⅰ期臨牀試驗。

該新藥為集團自主研發的達雷妥尤單克隆抗體生物類似藥,擬用於多發性骨髓瘤治療。

截至本公吿日,中國境內已上市的達雷妥尤單抗為Janssen-Cilag International NV的兆珂®(2019年7月獲批上市)。根據IQVIA CHPA數據(由IQVIA提供,IQVIA是全球領先的醫藥健康產業專業信息和戰略諮詢服務提供商;IQVIA CHPA數據代表中國境內100張牀位以上的醫院藥品銷售市場,不同的藥品因其各自銷售渠道佈局的不同,實際銷售情況可能與IQVIA CHPA數據存在不同程度的差異),2019年度,達雷妥尤單抗於中國境內的銷售額約為人民幣174萬元。截至2020年12月,集團現階段針對該新藥累計研發投入約為人民幣1624萬元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account